This is a synthetic peptide designed for use in combination with anti-WT1 Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
WT1
Reaktivität: Human
Wirt: Synthetic
WB, Imm, SDS
Applikationshinweise
Each Investigator should determine their own optimal working dilution for specific applications.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
Konzentration
1 mg/mL
Buffer
Final peptide concentration is 1 mg/mL in PBS.
Handhabung
Avoid repeated freeze-thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
Target
WT1
(Wilms Tumor 1 (WT1))
Hintergrund
WT1 is a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilm's tumors. Multiple transcript variants, resulting from alternative splicing at two coding exons, have been well characterized. There is also evidence for the use of non-AUG (CUG) translation initiation site upstream of, and in-frame with the first AUG, leading to additional isoforms.
Alias Symbols: AWT1, GUD, WAGR, WIT-2, WT33
Protein Interaction Partner: AREG,CIAO1,CREBBP,FHL2,PAWR,PAX2,PRKACA,TP53,TP63,TP73,U2AF2,UBE2I,WTAP,WTIP,PAWR,Pawr,TP53,U2AF2,UBE2I,WTAP